Multiple Therapeutic Applications of Metformin Moving Beyond Its Anti-Diabetic Role: A Systematic Review
Abstract
Introduction: Metformin is a commonly used anti-diabetic drug due to its safety, low cost, and strong glucose-lowering effects. Recent research studies have identified novel molecular targets and pathways for metformin, thereby expanding its potential beyond the treatment of Type 2 diabetes.
Methodology: This systematic review provides the latest updates on the therapeutic applications of metformin in multiple diseases. This systematic review follows the PRISMA guidelines, focusing on experimental studies systematic reviews and meta-analyses from PubMed, Scopus, Web of Science and Google scholar, the search terms ("Metformin"[MeSH] OR "Metformin") AND ("Cancer" OR "Cardiovascular Disease" OR "Neurodegenerative Disease" OR "Aging") AND ("Therapeutic Use" OR "Non-diabetic"). A comprehensive search yielded numerous studies, from which relevant and up-to-date papers were carefully selected.
Results: The review highlights the multifaceted applications of metformin in various diseases. Evidence demonstrates its positive effects on cardiovascular diseases, obesity, different types of cancer, and liver and kidney disorders. These findings suggest that metformin acts through diverse molecular mechanisms, exerting benefits that extend beyond glycemic control.
Conclusion: Based on the current literature, metformin exhibits a broad spectrum of therapeutic benefits, extending beyond its primary use in diabetes management. Its role in treating multiple diseases has marked it as a…
How strong is the evidence?
Evidence Hub reads this as a systematic review, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.